Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

Apr 29, 2021 | Press Releases

MARLBOROUGH, Mass., April 29, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Apr 10, 2021 | Press Releases

Data presented at the AACR Annual Meeting 2021MARLBOROUGH, Mass., April 10, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi...

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

Mar 25, 2021 | Press Releases

MARLBOROUGH, Mass., March 25, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Mar 11, 2021 | Press Releases

MARLBOROUGH, Mass., March 11, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

Mar 1, 2021 | Press Releases

MARLBOROUGH, Mass., March 1, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...